283 related articles for article (PubMed ID: 16099718)
21. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
[TBL] [Abstract][Full Text] [Related]
22. A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy.
Mamelak M; Swick T; Emsellem H; Montplaisir J; Lai C; Black J
Sleep Med; 2015 Jan; 16(1):52-8. PubMed ID: 25533539
[TBL] [Abstract][Full Text] [Related]
23. Long-term follow-up of patients with narcolepsy-cataplexy treated with sodium oxybate (Xyrem).
Alshaikh MK; Gacuan D; George S; Sharif M; Bahammam AS
Clin Neuropharmacol; 2011; 34(1):1-4. PubMed ID: 21206362
[TBL] [Abstract][Full Text] [Related]
24. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy.
Roth T; Dauvilliers Y; Guinta D; Alvarez-Horine S; Dynin E; Black J
J Sleep Res; 2017 Aug; 26(4):407-414. PubMed ID: 27807903
[TBL] [Abstract][Full Text] [Related]
25. Narcolepsy: treatment issues.
Roth T
J Clin Psychiatry; 2007; 68 Suppl 13():16-9. PubMed ID: 18078361
[TBL] [Abstract][Full Text] [Related]
26. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia.
Scharf MB; Baumann M; Berkowitz DV
J Rheumatol; 2003 May; 30(5):1070-4. PubMed ID: 12734908
[TBL] [Abstract][Full Text] [Related]
27. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy.
Mamelak M; Black J; Montplaisir J; Ristanovic R
Sleep; 2004 Nov; 27(7):1327-34. PubMed ID: 15586785
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
[TBL] [Abstract][Full Text] [Related]
29. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.
Ondo WG; Perkins T; Swick T; Hull KL; Jimenez JE; Garris TS; Pardi D
Arch Neurol; 2008 Oct; 65(10):1337-40. PubMed ID: 18852348
[TBL] [Abstract][Full Text] [Related]
30. Criteria for gauging response to sodium oxybate for narcolepsy.
Steffen AD; Lai C; Weaver TE
J Sleep Res; 2018 Aug; 27(4):e12628. PubMed ID: 29205601
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
32. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life.
Mathew NT; Landy S; Stark S; Tietjen GE; Derosier FJ; White J; Lener SE; Bukenya D
Headache; 2009 Jul; 49(7):971-82. PubMed ID: 19486178
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy.
Weaver TE; Cuellar N
Sleep; 2006 Sep; 29(9):1189-94. PubMed ID: 17040006
[TBL] [Abstract][Full Text] [Related]
34. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Bogan RK; Roth T; Schwartz J; Miloslavsky M
J Clin Sleep Med; 2015 Apr; 11(4):427-32. PubMed ID: 25580605
[TBL] [Abstract][Full Text] [Related]
35. Pharmacotherapy for cataplexy.
Houghton WC; Scammell TE; Thorpy M
Sleep Med Rev; 2004 Oct; 8(5):355-66. PubMed ID: 15336236
[TBL] [Abstract][Full Text] [Related]
36. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
37. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy.
Kushida CA; Shapiro CM; Roth T; Thorpy MJ; Corser BC; Ajayi AO; Rosenberg R; Roy A; Seiden D; Dubow J; Dauvilliers Y
Sleep; 2022 Jun; 45(6):. PubMed ID: 34358324
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active- and placebo-controlled, parallel-group, outpatient study.
Pytel J; Nagy G; Tóth A; Spellenberg S; Schwarz M; Répassy G
Clin Ther; 2007 Jan; 29(1):84-98. PubMed ID: 17379049
[TBL] [Abstract][Full Text] [Related]
39. Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav
Heo YA
CNS Drugs; 2022 May; 36(5):541-549. PubMed ID: 35357671
[TBL] [Abstract][Full Text] [Related]
40. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy.
Scharf MB; Brown D; Woods M; Brown L; Hirschowitz J
J Clin Psychiatry; 1985 Jun; 46(6):222-5. PubMed ID: 3888969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
